Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of AG-348 Tablet vs Capsule in Healthy Adults
NCT03397329Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mitapivat in pyruvate kinase deficiency (PKD) (2 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area Under the Curve to Last Measurable Concentration at 72 hours and 1 more. Started Oct 2017; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NCT03397329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03397329.